• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Liver cancer. >Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study
【24h】

Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study

机译：基于常规栓塞/化疗栓塞的型型血管症型患者患者患者的生存率延长了先进的肝细胞癌和保存肝功能：倾向分数匹配研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Sorafenib is the standard treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). However, the treatment outcome is not satisfactory. We retrospectively analyzed whether adding transarterial embolization/chemoembolization (TA(C)E)-based locoregional therapy to sorafenib can further improve treatment efficacy. Patients and Methods: We included 147 BCLC stage C HCC patients with Child-Turcotte-Pugh class A liver function and treated with sorafenib for analysis. Through propensity score matching, we divided patients into the combined treatment group (n = 63; patients received TA(C)E-based locoregional treatment and sorafenib) and the sorafenib monotherapy group (n = 63). We analyzed the effects of patients' clinical and tumor-related factors on their overall survival (OS) and time to tumor progression. Results: The OS was better in the combined treatment group than in the sorafenib monotherapy group (419 vs. 223 days, p = 0.028). In the Cox regression model, combined treatment, a lower baseline alpha-fetoprotein (AFP) level = 60 years were identified as independent factors for OS. Subgroup analysis demonstrated that patients with a higher baseline AFP level >400 ng/mL, age <60 years, tumors with branched portal venous tumorous thrombosis only or without extrahepatic metastasis benefited the most from combined treatment. Conclusion: Combining TA(C)E-based locoregional treatment with sorafenib resulted in better OS in patients with BCLC stage C HCC compared with sorafenib alone. TA(C)E-based locoregional treatment can be an adjunctive treatment to sorafenib for patients with advanced HCC and a satisfactory liver functional reserve. (C) 2018 S. Karger AG, Basel
机译：背景：Sorafenib是巴塞罗那临床肝癌（BCLC）第C肝细胞癌（HCC）患者的标准治疗方法。然而，治疗结果并不令人满意。我们回顾性地分析了是否添加常规栓塞/化疗（TA（c）e）与索拉苯基的型型浸润治疗可以进一步提高治疗效果。患者及方法：我们包括147级BCLC阶段C HCC患者，儿童扁桃-PUGH级肝功能，并用Sorafenib治疗进行分析。通过倾向得分匹配，我们将患者分成组合治疗组（n = 63;患者接受TA（c）基于e的型型型当前治疗和索拉非尼（N = 63）。我们分析了患者临床和肿瘤相关因素对整体存活（OS）和时间的影响，肿瘤进展。结果：组合治疗组OS比在索拉非尼单药治疗组中更好（419 vs.223天，P = 0.028）。在Cox回归模型中，组合治疗，较低的基线α-胎蛋白（AFP）水平= 60岁被鉴定为OS的独立因子。亚组分析表明，患者患者较高的基线AFP水平> 400ng / ml，年龄<60岁，肿瘤的分支门静脉肿瘤血栓形成仅或没有脱发的转移使最多来自组合治疗。结论：与Sorafenib患者单独使用Sorafenib与索拉非尼的患者患者组合基于TA（c）e的型型局部疗效。 TA（c）基于E的型局部处理可以是索拉非尼的患者对先进的HCC患者和令人满意的肝功能储备进行辅助治疗。 （c）2018年S. Karger AG，巴塞尔

著录项

  • 来源
    《Liver cancer.》 |2019年第3期|共17页
  • 作者

    Chien Shih-Chieh; Chen Chiung-Yu; Cheng Pin-Nan; Liu Yi-Shan; Cheng Hsiu-Chi; Chuang Chiao-Hsiung; Chang Ting-Tsung; Chiu Hong-Chi; Lin Yih-Jyh; Chiu Yen-Cheng;

  • 作者单位

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Radiol;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

    Natl Cheng Kung Univ Coll Med Natl Cheng Kung Univ Hosp Div Transplant Surg Dept Surg Tainan;

    Natl Cheng Kung Univ Natl Cheng Kung Univ Hosp Coll Med Div Gastroenterol &

    Hepatol Dept Med;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Sorafenib; Transarterial chemoembolization; Advanced HCC; Child-Pugh A;

    机译：索拉非尼;rantarterial chemoembolization;高级HCC;Child-Pugh A;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号